Compare
Amgen vs Biogen (AMGN vs BIIB)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Biogen (BIIB) +61.9%; so far this year the figures are +40.7% and +41.1%.
Amgen is the larger company by market value, about 6.8 times the size of Biogen.
On trailing earnings, AMGN trades at 26.7 times and BIIB at 107.0 times.
Revenue grew +8.2% at AMGN and +2.3% at BIIB over the last year.
AMGN yields 2.16%. BIIB pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | BIIB | |
|---|---|---|
| Price | $460.42 | $248.35 |
| 1-day | +0.03% | +1.81% |
| YTD | +40.67% | +41.12% |
| 1 year | +43.94% | +61.87% |
| 3 years | +76.51% | +3.64% |
| Market cap | $249.1B | $36.7B |
| P/E | 26.7 | 107.0 |
| P/S | 6.40 | 3.57 |
| P/B | 17.35 | 1.94 |
| Revenue growth | +8.20% | +2.30% |
| EPS growth | +33.30% | -78.90% |
| Gross margin % | 70.9 | 74.0 |
| Net margin % | 24.1 | 3.4 |
| ROE % | 65.4 | 1.8 |
| Debt / equity | 3.76 | 0.39 |
| FCF yield % | 3.8 | 5.6 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 0.33 |
| RSI (14) | 60.5 | 57.0 |
| Technical rating |